Category Archives: Antipsychotic medication

Essential Components of First-Episode Psychosis Services

Posted on May 1, 2013 by rkennedy

A study published in May 1st, 2013 Psychiatric Services identified essential evidence-based components of first-episode psychosis services. The research took place in two stages. First a systematic literature review, then, a consensus-building technique, the Delphi, was used with an international … Continue reading →

Posted in Addiction, Adherence, Antipsychotic medication, Early intervention, Measurement-based care, Mental health, Metabolic screening, Professionalism, Psychosis, Schizophrenia | Comments Off

The Nature of Relapse in Schizophrenia

Posted on February 26, 2013 by rkennedy

Discontinuation of treatment in schizophrenia results in very high relapse rates, even after a single psychotic episode. A new review in BMC Psychiatry asserts that multiple relapses characterze the course of illness in most patients with schizophrenia, yet the nature … Continue reading →

Posted in Adherence, Antipsychotic medication, Neuroscience, Psychosis, Relapse, Schizophrenia | Comments Off

Beyond Dopamine: Glutamate as a Target in Schizophrenia

Posted on July 26, 2012 by rkennedy

An interesting review in ISRN Pharmacology, a peer-reviewed, open access journal, describes that for the last 60 years, antipsychotic pharmacology targeting antagonism of dopamine (DA) D2 receptors have been the primary treatment choice for schizophrenia. The clinical improvement seen by … Continue reading →

Posted in Antipsychotic medication, Cognition, Negative symptoms, Schizophrenia | Comments Off

Non-adherence to Antipsychotics and Cardiometabolic Medication Result in Health Care Utilization and Costs

Posted on June 18, 2012 by rkennedy

A new study in Psychiatric Services examined the association between adherence to antipsychotic and cardiometabolic medication and the use of health care services and expenditures. A total of 87,015 unique patients with schizophrenia who received at least one antipsychotic medication … Continue reading →

Posted in Adherence, Antipsychotic medication, Cardiovascular Risk Factors, Metabolic screening, Psychosis, Schizophrenia | Comments Off

Impact of Preexisting Metabolic Risk Factors on the Choice of Antipsychotics

Posted on December 16, 2011 by rkennedy

A study in this month’s Psychiatric Services examined the association between patients’ preexisting metabolic risk factors and the physician’s choice of antipsychotic agent based on its propensity to cause metabolic side effects. Over a span of 3 years, 1,898 office-based … Continue reading →

Posted in Antipsychotic medication, Metabolic screening | Comments Off

Psychiatrists fail to monitor patients for metabolic side-effects of medication

Posted on August 15, 2011 by rkennedy

According to a new study in Psychological Medicine, people treated in psychiatric settings are receiving inadequate medical monitoring while taking antipsychotic medication New research from the University of Leicester demonstrates that psychiatrists are not offering adequate checks for metabolic complications … Continue reading →

Posted in Antipsychotic medication, Metabolic screening, Schizophrenia, Treatment | Comments Off